Hyperglycaemia and cardiovascular disease

Journal of Internal Medicine

Volumn 262, Issue 2, 2007, Pages 145-156

  Bartnik, M ^a   Norhammar, A ^b   Ryden L ^b  

^a Kärnsjukhuset ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Coronary artery disease; Diabetes; Impaired glucose tolerance; Prognosis

Indexed keywords

ABDOMINAL OBESITY; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSURIA; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; PROGNOSIS; RISK FACTORS;

EID: 34447630674     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01831.x     Document Type: Conference Paper

References (94)

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979 28 : 1039 57.
2. WHO Expert Committee on Diabetes Mellitus. Second Report. Geneva : WHO, 1980, Technical Report Series 646.
3. Report of the WHO Consultation, Definition, Diagnosis and Classification of Diabetes mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes mellitus. Geneva : World Health Organisation, Department of Non-communicable Disease Surveillance, 1999.
4. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997 20 : 1183 97.
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004 27 (Suppl. 1 S5 10.
6. Barach JH. Paul Langerhans, 1847-1888. Diabetes 1952 1 : 411 3.
7. Levine R. Historical development of the theory of pancreatic diabetes by Oscar Minkowsky. Diabetes 1989 38 : 1 6.
8. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. 1922. CMAJ 1991 145 : 1281 6.
9. Levine SA. Angina pectoris. Some clinical considerations. JAMA 1922 79 : 928 33.
10. Levine SA. Coronary thrombosis: its various clinical features. Medicine 1929 8 : 245 418.
11. Cruickshank N. Coronary thrombosis and myocardial infarction. Br Med J 1931 1 : 618 9.
12. Goldberger E, Alesio J, Woll F. The significance of hyperglycaemia in myocardial infarction. N Y State J Med 1945 45 : 391 3.
13. Wahlberg F. Intravenous glucose tolerance in myocardial infarction, angina pectoris and intermittent claudication. Acta Med Scand 1966 80 (Suppl. 453 61.
14. Opie LH, Stubbs WA. Carbohydrate metabolism in cardiovascular disease. Clin Endocrinol Metab 1976 5 : 703 29.
15. Laakso M. Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes 1999 48 : 937 42.
16. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular diseases and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990 65 : 344 9.
17. Stamler J, Vaccaro O, Neaton JD, Wenworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 44.
18. Anderson DKG, Svärdsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 1995 18 : 1534 43.
19. Sratton IM, Adler AJ, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). Br Med J 2000 321 : 405 12.
20. Hanefeld M, Fischer S, Julius U et al., The DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996 39 : 1577 83.
21. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause mortality and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998 21 : 1167 72.
22. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997 18 : 1569 82.
23. Norhammar A, Malmberg K, Rydén L et al. Under utilisation of evidence-based treatment partially explains the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J 2003 24 : 838 44.
24. Amato L, Paolisso G, Cacciatore F et al. Congestive heart failure predicts the development of noninsulin dependent diabetes mellitus in the elderly. Diabetes Metab 1997 23 : 213 8.
25. Norhammar A, Tenerz Å, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002 359 : 2140 4.
26. Bartnik M, Malmberg K, Hamsten A et al. Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004 256 : 288 97.
27. Bartnik M, Ryden L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004 25 : 1880 90.
28. Jarret RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet 1976 2 : 1009 12.
29. Stamler R, Stamler J. Asymptomatic hyperglycaemia and coronary heart disease. A series of papers by the International Collaborative Group, based on studies in fifteen populations. J Chron Dis 1979 32 : 683 91.
30. Baron A. Impaired glucose tolerance as a disease. Am J Cardiol 2001 88 (Suppl. 16H 9H.
31. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980 1 : 1373 6.
32. Rodriguez BL, Lau N, Bruchfiel CM et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality. The Honolulu Heart Program. Diabetes Care 1999 22 : 1262 5.
33. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulindependent diabetes mellitus. The Verona Diabetes Study. Circulation 1997 96 : 1750 4.
34. Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study and the Helsinki Policemen Study. Diabetes Care 1998 21 : 360 7.
35. Laakso M, Kuusisto J. Understanding patient needs. Diabetology for cardiologists. Eur Heart J 2003 5 (Suppl. B B5 13.
36. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95.783 individuals followed for 12.4 years. Diabetes Care 1999 22 : 233 40.
37. The DECODE study group on behalf on the European Diabetes Epidemiology group. Glucose tolerance and cardiovascular mortality. Arch Intern Med 2001 161 : 397 404.
38. Meigs JB, Nathan DM, Wilson WF, Cupples A, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998 128 : 524 33.
39. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003 108 : 1527 32.
40. Jarrett JR. Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease: chicken, egg, or neither? Diabetologia 1984 26 : 99 102.
41. Edelstein SL, Knowler WC, Bain RP et al. Predictors of progression from impaired glucose tolerance to NIDDM. An analysis of six prospective studies. Diabetes 1997 46 : 701 10.
42. Aronson D, Rayfield EJ, Cheseboro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997 126 : 296 306.
43. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990 131 : 443 53.
44. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes. JAMA 1990 263 : 2893 8.
45. Stern MP. Diabetes and cardiovascular disease: the 'common soil' hypothesis. Diabetes 1995 44 : 369 74.
46. Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diabet Med 1996 13 : S15 9.
47. Dowse GK, Zimmet PZ, Collins VR. Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes 1996 45 : 1367 72.
48. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. Br Med J 1995 310 : 555 9.
49. Will JC, Galuska DA, Ford ES, Mokdad A, Calle E. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol 2001 30 : 540 6.
50. Bennet AM, Brismar K, Hallqvist J, Reuterwall C, de Faire U. The risk of myocardial infarction is enhanced by a synergistic interaction between serum insulin and smoking. Eur J Endocrinol 2002 147 : 641 7.
51. Agewall S. Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk. J Intern Med 1999 246 : 489 95.
52. Båvenholm P, de Faire U, Landou C et al. Progression of coronary artery disease in young male post-infarction patients is linked to disturbancies of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Heart J 1998 19 : 402 10.
53. Duncan BB, Scmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1999 22 : 767 72.
54. Pradhan AD, Mason JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001 286 : 327 34.
55. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002 23 : 831 4.
56. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000 342 : 836 43.
57. Reaven G. Age and glucose intolerance. Diabetes Care 2003 26 : 539 40.
58. Imbeault P, Prins JB, Stolic JB et al. Aging per se does not influence glucose homeostasis. Diabetes Care 2003 26 : 480 4.
59. Hu FB, Manson JE, Stampfer MJ et al. Diet, life style, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001 345 : 790 7.
60. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997 34 : 25 33.
61. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 : 813 20.
62. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001 18 : 945 59.
63. Du XL. Hyperglycaemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000 97 : 1222 6.
64. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004 24 : 816 23.
65. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001 108 : 635 6.
66. Kawano H, Motoyama T, Hirashima O et al. Hyperglycemia rapidly suppress flow-mediated endothelium-dependent vasodilatation of brachial artery. J Am Coll Cardiol 1999 34 : 146 54.
67. Ceriello A, Taboga C, Tonutti L et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia in endothelial dysfunction and oxidative stress generation. Effects of short- and long-term simvastatin treatment. Circulation 2002 106 : 1211 8.
68. Cosentino F, Eto M, De Paolis P et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003 107 : 1017 23.
69. Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation 2002 106 : 2067 72.
70. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000 404 : 787 90.
71. Lusis AJ. Atherosclerosis. Nature 2000 407 : 233 41.
72. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001 24 : 1476 85.
73. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3- methylglutarylcoenzyme A reductase inhibitors. Arterioscler Throm Vasc Biol 2001 21 : 1712 9.
74. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006 29 : 1220 6.
75. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999 281 : 1291 7.
76. Fox CS, Coady S, Sorlie PD et al. Trends in cardiovascular complications of diabetes. JAMA 1999 281 : 1291 7.
77. Malmberg K, Yusuf S, Gerstein H et al., for the OASIS Registry Investigators. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction. Results of the OASIS (Organisation to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000 102 : 1014 9.
78. McGiure DK, Emanuelsson H, Granger CB et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study. Eur Heart J 2000 21 : 1750 8.
79. Malmberg K, Norhammar A, Wedel H, Rydén L. Glucometabolic state at admission. important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long term results from the DIGAMI study. Circulation 1999 99 : 2626 32.
80. Norhammar AM, Rydén L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care 1999 22 : 1827 31.
81. Suleiman M, Hammerman H, Boulos M et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction. A prospective study. Circulation 2005 111 : 754 60.
82. Malmberg K, Ryden L, Wedel H et al., DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005 26 : 650 61.
83. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Öhrvik J, Rydén L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004 25 : 1990 7.
84. Lenzen M, Rydén L, John Öhrvik J et al., on behalf of the Euro Heart Survey Investigators. Diabetes known or newly detected but not impaired glucose regulation has a negative influence on 1-year outcome in patients with coronary artery disease. A report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006 27 : 2969 74.
85. Muhlestein JB, Anderson JL, Horne BD et al., Intermountain Heart Collaborative Study Group. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003 146 : 351 8.
86. Lauruschkat AH, Arnrich B, Albert AA et al. Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. Circulation 2005 112 : 2397 402.
87. Stettler C, Allemann S, Juni P et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006 152 : 27 38.
88. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 344 : 1343 50.
89. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
90. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002 359 : 2072 7.
91. Ramachandran A, Snehalatha C, Mary S et al., Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006 49 : 289 97.
92. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006 368 : 1096 105.
93. Chiasson JL, Josse RG, Gomis R et al., STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 290 : 486 94.
94. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 28 : 88 136.